Berenberg Bank Analysts Give MorphoSys (ETR:MOR) a €150.00 Price Target

Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys (ETR:MOR) in a research report report published on Monday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys and gave the stock a buy rating in a report on Thursday, March 19th. Goldman Sachs Group restated a neutral rating on shares of MorphoSys in a report on Wednesday, January 22nd. Deutsche Bank set a €129.00 ($150.00) target price on MorphoSys and gave the stock a buy rating in a report on Tuesday, March 3rd. JPMorgan Chase & Co. restated a buy rating on shares of MorphoSys in a report on Thursday, March 19th. Finally, Independent Research set a €119.00 ($138.37) target price on MorphoSys and gave the stock a buy rating in a report on Monday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of €122.88 ($142.88).

MOR opened at €91.65 ($106.57) on Monday. The business has a 50 day moving average price of €99.88 and a 200 day moving average price of €108.17. MorphoSys has a twelve month low of €79.70 ($92.67) and a twelve month high of €146.30 ($170.12). The company has a debt-to-equity ratio of 9.78, a quick ratio of 7.63 and a current ratio of 7.80. The firm has a market cap of $3.06 billion and a P/E ratio of -30.13.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Featured Article: What is a stock split?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.